vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and LESAKA TECHNOLOGIES INC (LSAK). Click either name above to swap in a different company.

LESAKA TECHNOLOGIES INC is the larger business by last-quarter revenue ($178.7M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 1.4%). Over the past eight quarters, LESAKA TECHNOLOGIES INC's revenue compounded faster (13.7% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

ESPR vs LSAK — Head-to-Head

Bigger by revenue
LSAK
LSAK
1.1× larger
LSAK
$178.7M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+142.3% gap
ESPR
143.7%
1.4%
LSAK
Faster 2-yr revenue CAGR
LSAK
LSAK
Annualised
LSAK
13.7%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ESPR
ESPR
LSAK
LSAK
Revenue
$168.4M
$178.7M
Net Profit
$3.6M
Gross Margin
31.4%
Operating Margin
50.6%
1.2%
Net Margin
2.0%
Revenue YoY
143.7%
1.4%
Net Profit YoY
111.2%
EPS (diluted)
$0.32
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
LSAK
LSAK
Q4 25
$168.4M
$178.7M
Q3 25
$87.3M
$171.4M
Q2 25
$82.4M
$168.5M
Q1 25
$65.0M
$161.4M
Q4 24
$69.1M
$176.2M
Q3 24
$51.6M
$153.6M
Q2 24
$73.8M
$146.0M
Q1 24
$137.7M
$138.2M
Net Profit
ESPR
ESPR
LSAK
LSAK
Q4 25
$3.6M
Q3 25
$-31.3M
$-4.3M
Q2 25
$-12.7M
$-28.4M
Q1 25
$-40.5M
$-22.1M
Q4 24
$-32.5M
Q3 24
$-29.5M
$-4.5M
Q2 24
$-61.9M
$-5.0M
Q1 24
$61.0M
$-4.0M
Gross Margin
ESPR
ESPR
LSAK
LSAK
Q4 25
31.4%
Q3 25
30.9%
Q2 25
28.9%
Q1 25
27.5%
Q4 24
25.7%
Q3 24
22.6%
Q2 24
22.6%
Q1 24
22.0%
Operating Margin
ESPR
ESPR
LSAK
LSAK
Q4 25
50.6%
1.2%
Q3 25
-11.4%
0.2%
Q2 25
8.6%
-16.7%
Q1 25
-34.0%
0.4%
Q4 24
-6.4%
0.3%
Q3 24
-31.0%
-0.0%
Q2 24
3.5%
0.2%
Q1 24
52.5%
0.6%
Net Margin
ESPR
ESPR
LSAK
LSAK
Q4 25
2.0%
Q3 25
-35.9%
-2.5%
Q2 25
-15.4%
-16.9%
Q1 25
-62.2%
-13.7%
Q4 24
-18.4%
Q3 24
-57.2%
-3.0%
Q2 24
-83.9%
-3.4%
Q1 24
44.3%
-2.9%
EPS (diluted)
ESPR
ESPR
LSAK
LSAK
Q4 25
$0.32
$0.04
Q3 25
$-0.16
$-0.05
Q2 25
$-0.06
$-0.40
Q1 25
$-0.21
$-0.27
Q4 24
$-0.14
$-0.40
Q3 24
$-0.15
$-0.07
Q2 24
$-0.33
$-0.08
Q1 24
$0.34
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
LSAK
LSAK
Cash + ST InvestmentsLiquidity on hand
$167.9M
$69.5M
Total DebtLower is stronger
$216.8M
Stockholders' EquityBook value
$-302.0M
$180.6M
Total Assets
$465.9M
$704.6M
Debt / EquityLower = less leverage
1.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
LSAK
LSAK
Q4 25
$167.9M
$69.5M
Q3 25
$92.4M
$72.2M
Q2 25
$86.1M
$76.5M
Q1 25
$114.6M
$71.0M
Q4 24
$144.8M
$60.6M
Q3 24
$144.7M
$49.7M
Q2 24
$189.3M
$59.1M
Q1 24
$226.6M
$55.2M
Total Debt
ESPR
ESPR
LSAK
LSAK
Q4 25
$216.8M
Q3 25
$208.1M
Q2 25
$200.8M
Q1 25
$194.7M
Q4 24
$148.7M
Q3 24
$148.5M
Q2 24
$143.2M
Q1 24
$135.7M
Stockholders' Equity
ESPR
ESPR
LSAK
LSAK
Q4 25
$-302.0M
$180.6M
Q3 25
$-451.4M
$170.4M
Q2 25
$-433.5M
$161.6M
Q1 25
$-426.2M
$185.2M
Q4 24
$-388.7M
$193.3M
Q3 24
$-370.2M
$184.2M
Q2 24
$-344.2M
$175.9M
Q1 24
$-294.3M
$173.1M
Total Assets
ESPR
ESPR
LSAK
LSAK
Q4 25
$465.9M
$704.6M
Q3 25
$364.0M
$652.9M
Q2 25
$347.1M
$653.7M
Q1 25
$324.0M
$649.2M
Q4 24
$343.8M
$640.6M
Q3 24
$314.1M
$551.9M
Q2 24
$352.3M
$558.5M
Q1 24
$373.1M
$551.5M
Debt / Equity
ESPR
ESPR
LSAK
LSAK
Q4 25
1.20×
Q3 25
1.22×
Q2 25
1.24×
Q1 25
1.05×
Q4 24
0.77×
Q3 24
0.81×
Q2 24
0.81×
Q1 24
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
LSAK
LSAK
Operating Cash FlowLast quarter
$45.2M
$-10.9M
Free Cash FlowOCF − Capex
$-14.8M
FCF MarginFCF / Revenue
-8.3%
Capex IntensityCapex / Revenue
0.0%
2.2%
Cash ConversionOCF / Net Profit
-2.99×
TTM Free Cash FlowTrailing 4 quarters
$-15.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
LSAK
LSAK
Q4 25
$45.2M
$-10.9M
Q3 25
$-4.3M
$8.9M
Q2 25
$-31.4M
$-9.1M
Q1 25
$-22.6M
$10.7M
Q4 24
$-35.0M
$-9.2M
Q3 24
$-35.3M
$-4.1M
Q2 24
$-7.2M
$5.7M
Q1 24
$53.8M
$19.2M
Free Cash Flow
ESPR
ESPR
LSAK
LSAK
Q4 25
$-14.8M
Q3 25
$4.9M
Q2 25
$-13.2M
Q1 25
$7.8M
Q4 24
$-15.5M
Q3 24
$-35.5M
$-8.1M
Q2 24
$-7.3M
$937.0K
Q1 24
$53.8M
$16.2M
FCF Margin
ESPR
ESPR
LSAK
LSAK
Q4 25
-8.3%
Q3 25
2.9%
Q2 25
-7.8%
Q1 25
4.9%
Q4 24
-8.8%
Q3 24
-68.7%
-5.3%
Q2 24
-9.9%
0.6%
Q1 24
39.0%
11.7%
Capex Intensity
ESPR
ESPR
LSAK
LSAK
Q4 25
0.0%
2.2%
Q3 25
0.0%
2.3%
Q2 25
0.0%
2.4%
Q1 25
0.0%
1.7%
Q4 24
0.0%
3.6%
Q3 24
0.3%
2.6%
Q2 24
0.1%
3.2%
Q1 24
0.1%
2.1%
Cash Conversion
ESPR
ESPR
LSAK
LSAK
Q4 25
-2.99×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

LSAK
LSAK

Telecom Products And Services$82.0M46%
Processing Fees$37.6M21%
Enterprise Segment$14.5M8%
Rest Of Africa$10.9M6%
Technology Products$8.6M5%
Insurance Revenue$7.9M4%
Lending Revenue$7.2M4%
Other$6.7M4%
Interest From Customer$2.1M1%
Other Products And Services$1.2M1%

Related Comparisons